-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Stryker delivered a challenging Q1 2026 with adjusted EPS of $2.60 missing consensus by $0.38 and declining 8.5% from Q1 2025. Net sales reached $6.0B (+2.6% Y/Y) with 2.4% organic growth but missed expectations by $330M, impacted by a cybersecurity incident. We think the March 11 cybersecurity incident materially disrupted operations across segments, contributing to margin compression of 180 bps to 21.1% and $118M in incident-related costs. Management maintained full-year 2026 guidance of 8.0%-9.5% organic growth and $14.90-$15.10 EPS despite Q1 shortfall, signaling confidence in operational recovery. We see the strategic restructuring creating the new Ortho Tech business as positive, combining orthopaedic instruments with Mako technologies to simplify customer experience. The guidance implies significant acceleration in remaining quarters, though we expect continued near-term headwinds from operational disruptions and margin pressure.